If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | lyophilized form |
| Typical purity | 95 percent or higher by RP-HPLC | value depends on method |
| Storage temperature | minus 20 degrees Celsius or below | desiccated, protected from light |
| Reconstitution solvent | bacteriostatic water | sterile saline also used |
| Primary assay | RP-HPLC with UV detection | often paired with mass spectrometry |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
=== Names === Selegiline is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while selegiline hydrochloride is the USANTooltip United States Adopted Name. The word "selegiline" is pronounced (sə-LEJ-i-leen) or as "seh-LEH-ji-leen". Selegiline is also known as L-deprenyl, L-deprenil, L-deprenalin, L-deprenaline, L-phenylisopropylmethylpropinylamine, and L-E-250. It should not be confused with the racemic form, deprenyl (E-250), or with the dextrorotatory enantiomer, D-deprenyl, which are distinct substances. Major brand names of selegiline include Eldepryl, Jumex, and Movergan (oral tablet and/or capsule), Zelapar (orally disintegrating tablet or ODT), and Emsam (transdermal patch). Selegiline has been marketed under more than 70 brand names worldwide. The brand name "Emsam" was derived from the names of two children, Emily and Samuel, of one of the executives at Somerset Pharmaceuticals, the developer of Emsam.
Adrenocorticotropic hormone release is triggered by corticotropin-releasing hormone and inhibited by rising glucocorticoid levels. The gonadotropins—follicle-stimulating hormone and luteinizing hormone regulate the functions of the gonads in both sexes. Follicle-stimulating hormone stimulates sex cell production; luteinizing hormone stimulates gonadal hormone production. Gonadotropin levels rise in response to gonadotropin-releasing hormone. Negative feedback of gonadal hormones inhibits gonadotropin release. Prolactin promotes milk production in human females. Its secretion is prompted by prolactin-releasing hormone and inhibited by prolactin-inhibiting hormone. The intermediate lobe of the pituitary gland secretes only one enzyme that is melanocyte stimulating hormone. It is linked with the formation of the black pigment in our skin called melanin. The neurohypophysis stores and releases two hypothalamic hormones:
=== Regime type and polarization === Hybrid regimes are more vulnerable to coups than very authoritarian states or democratic states. A 2021 study found that democratic regimes were not substantially more likely to experience coups. A 2015 study finds that terrorism is strongly associated with re-shuffling coups. A 2016 study finds that there is an ethnic component to coups: "When leaders attempt to build ethnic armies, or dismantle those created by their predecessors, they provoke violent resistance from military officers." Another 2016 study shows that protests increase the risk of coups, presumably because they ease coordination obstacles among coup plotters and make international actors less likely to punish coup leaders. A third 2016 study finds that coups become more likely in the wake of elections in autocracies when the results reveal electoral weakness for the incumbent autocrat. A fourth 2016 study finds that inequality between social classes increases the likelihood of coups. A fifth 2016 study finds no evidence that coups are contagious; one coup in a region does not make other coups in the region likely to follow. One study found that coups are more likely to occur in states with small populations, as there are smaller coordination problems for coup-plotters. In autocracies, the frequency of coups seems to be affected by the succession rules in place, with monarchies with a fixed succession rule being much less plagued by instability than less institutionalized autocracies.
Ricin is very toxic if inhaled, injected, or ingested. It can also be toxic if dust contacts the eyes or if it is absorbed through damaged skin. It acts as a toxin by inhibiting protein synthesis. Ricin is resistant, but not impervious, to digestion by peptidases. By ingestion, the pathology of ricin is largely restricted to the gastrointestinal tract, where it may cause mucosal injuries. With appropriate treatment, most patients will make a good recovery.
== References == This article incorporates material from the Citizendium article "Drugs banned from the Olympics", which is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License but not under the GFDL.
Sources: en.wikipedia.org
== Application == Microtox has a variety of environmental and industrial applications. Common applications are for testing the toxicity of both marine and freshwater, as well as sediments for pesticides and other inorganic and organic chemicals. Drinking water: Microtox is used to test drinking water sources in many areas where either accidental or deliberate contamination is possible. Toxic contaminants in drinking water are indicated by a change in the color or intensity of light, or by a change in the rate of oxygen use. Lakes and rivers: Microtox is used to test the toxicity of lake and river sediments contaminated by metals or nonspecific contaminants. The Solid-Phase test is used for sediments, while either the Basic test or the 100% test is used for pore water. Sediment testing: Microtox is used to test and evaluate the toxicity of various marine and freshwater sediments contaminated by metals and organics. Aqueous extracts of contaminated soils, drilling muds, and sludge. Microtox data may be used to establish apparent effects threshold (AET), sediment quality standards and used for NPDES permits, as well as Superfund cleanup levels. Industrial: This bioassay is used in the assessment of the toxicity of complex industrial effluent sources. It is a cost-effective way for monitoring and testing large numbers of samples. Microtox can also be applied as an early warning system (EWS) and aid in detecting the presence of toxic materials, as well as predict the outcomes of other bioassays and tests.
Pulmonary arterial hypertension (PAH) is a syndrome in which the blood pressure in the pulmonary arteries and pulmonary arterioles (the blood vessels located proximal to the capillary bed, the site of oxygen exchange in the lungs) is elevated. This pre-capillary pulmonary artery pressure being elevated is essential, and by definition a mean pulmonary artery pressure greater than 20 mmHg as measured by a right heart catheterization is required for the diagnosis. This pre-capillary pulmonary hypertension is confirmed with measuring pulmonary vascular resistance being greater than 3 Woods Units. A pulmonary artery wedge pressure being less than 15 mmHg (also measured by right heart catheterization) excludes post-capillary bed (in the veins distal to the capillary bed) pulmonary hypertension. Pulmonary arterial hypertension is a subgroup of pulmonary hypertension and is categorized as World Health Organization as group 1. PAH is further subdivided into various categories based on the cause, including idiopathic, heritable, drug and toxin induced, PAH associated with specific diseases (such as connective tissue disorders, portal hypertension or HIV), PAH that is responsive to vasodilators, PAH with venous or capillary involvement, and persistent PAH in the newborn period. If left untreated, the increased pulmonary vascular resistance will eventually lead to right heart failure and death. In the 1980s (before disease specific treatments became available) the 5 year survival rate was 34%.
Difficulty with walking Tingling or loss of sensation (numbness) in hands and feet Loss of tendon reflexes Loss of muscle function or paralysis of the lower legs Mental confusion/speech difficulties Pain Involuntary eye movements (nystagmus) Vomiting A selective impairment of the large proprioceptive sensory fibers without motor impairment can occur and present as a prominent sensory ataxia, which is a loss of balance and coordination due to loss of the proprioceptive inputs from the periphery and loss of position sense.
Rats that were fed a standard diet showed a progressive degradation of myelin, on day 14 post DAI it was evident that myelin sheaths have collapsed, dissolved or disappeared from the injured axons. For the axons with remaining myelin, the myelin was becoming thinner. Rats that were served ketogenic diets presented axons with thicker myelin in comparison to the standard diet rats. The marker that was used to determine axonal injury in this study was amyloid precursor protein (APP). Rats that were fed a standard diet and an uptake of APP, leading to an increase in damaged/injured axons.
terms for any measured surfaces. Leighton et al. demonstrated that Gaussian fit data is not accurate for modelling any engineered surfaces and went on to demonstrate that early running of the surfaces results in a gradual transition which significantly changes the surface topography, load carrying capacity and friction. The exact solutions for
Sources: en.wikipedia.org
=== Actin binding === Thymosin β4 was initially perceived as a thymic hormone. However this changed when it was discovered that it forms a 1:1 complex with G (globular) actin, and is present at high concentration in a wide range of mammalian cell types. When appropriate, G-actin monomers polymerize to form F (filamentous) actin, which, together with other proteins that bind to actin, comprise cellular microfilaments. Formation by G-actin of the complex with β-thymosin (= "sequestration") opposes this. Due to its profusion in the cytosol and its ability to bind G-actin but not F-actin, thymosin β4 is regarded as the principal actin-sequestering protein in many cell types. Thymosin β4 functions like a buffer for monomeric actin as represented in the following reaction: F-actin ↔ G-actin + Thymosin β4 ↔ G-actin/Thymosin β4 Release of G-actin monomers from thymosin β4 occurs as part of the mechanism that drives actin polymerization in the normal function of the cytoskeleton in cell morphology and cell motility. The sequence LKKTET, which starts at residue 17 of the 43-aminoacid sequence of thymosin beta-4, and is strongly conserved between all β-thymosins, together with a similar sequence in WH2 domains, is frequently referred to as "the actin-binding motif" of these proteins, although modelling based on X-ray crystallography has shown that essentially the entire length of the β-thymosin sequence interacts with actin in the actin-thymosin complex.
=== Treatment === The development of the science of microsurgery over the last 40 years has provided several treatment options for a traumatic amputation, depending on the patient's specific trauma and clinical situation:
At the industry's peak, 1,300,000 short tons (1,200,000 t) of ice was produced annually for refrigerator car use. On the East Coast of the United States, in 1920, the company Fruit Growers Express (FGE) was established and owned by a consortium of eastern railroads to serve the wholesale market for refrigerated produce delivered by railcar. In addition to operating and servicing refrigerated railcars, FGE became a major manufacturer of insulated boxcars and mechanical refrigerated cars.
Dent, London, 1981) ISBN 978-0-460-04535-3 Is Life an Astronomical Phenomenon? (University College Cardiff Press, 1982) ISBN 9780906449493 Why Neo-Darwinism Does Not Work (with Fred Hoyle) (University College Cardiff Press, 1982) ISBN 9780906449509 Proofs that Life is Cosmic (with Fred Hoyle) (Institute of Fundamental Studies, Sri Lanka, Memoirs no.1, 1982) From Grains to Bacteria (with Fred Hoyle) (University College Cardiff Press, 1984) ISBN 9780906449646 Fundamental Studies and the Future of Science (ed.) (University College Cardiff Press, 1984) ISBN 9780906449578 Living Comets (with Fred Hoyle) (University College Cardiff Press, 1985) ISBN 9780906449790 Archaeopteryx, the Primordial Bird: A Case of Fossil Forgery (with Fred Hoyle) (Christopher Davies, Swansea, 1986) ISBN 9780715406656 The Theory of Cosmic Grains (with Fred Hoyle) (Kluwer, Dordrecht, 1991) ISBN 9780792311898 Life on Mars? The Case for a Cosmic Heritage (with Fred Hoyle) (Clinical Press, Bristol, 1997) ISBN 9781854570413 Astronomical Origins of Life: Steps towards Panspermia (with Fred Hoyle) (Kluwer, Dordrecht, 2000) ISBN 9780792360810 Cosmic Dragons: Life and Death on Our Planet (Souvenir Press, London, 2001) ISBN 9780285636064 Fred Hoyle's Universe (ed. with G. Burbidge and J. Narlikar) (Kluwer, Dordrecht, 2003) ISBN 9781402014154 A Journey with Fred Hoyle (World Scientific, Singapore, 2005) ISBN 9789812565792 Comets and the Origin of Life (with J. Wickramasinghe and W.
The Moloney electrode, developed in 1921, is "designed to more accurately and rapidly determine the acidity of bacterial culture broths used in antitoxin and vaccine production." Hermann F. Schott (1904–1986) in his 1933 Ph.D. thesis gave a brief description of the Moloney electrode and its use. At Connaught Laboratories during the 1920s, Moloney dealt with the diphtheria toxin, whose preparation he directed from 1924. With Charles Beecher Weld (1899–1991), he developed the first diphtheria toxoid in North America. Moloney helped to develop a detection test for diphtheria toxin (the "Moloney test") and established methods for the detection and purification of tetanus toxin and contributed to the elucidation of its antigen structure. From 1931 he headed the "Chemistry in Relation to Hygiene" department of the School of Hygiene (dealing with microbiology) of the University of Toronto. He was part of the group that successfully developed methods for producing penicillin on a large scale during WW II. Moloney and co-workers were also able to prepare a polyvalent immune serum against gas gangrene. With Anthony L. Tosoni, he provided the basis for a new method for the production of penicillin in large quantities. Moloney was deputy director of Connaught Laboratories from 1925 until his retirement in 1961, but continued to work for the company as a researcher and consultant into his ninth decade. His last publications in the early 1970s dealt with insulin resistance and insulin as antigen. Moloney held 7 U.S.
Sources: en.wikipedia.org
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.
Most suppliers state a purity of ninety-five percent or higher by reversed-phase chromatography. Values below that threshold indicate a larger proportion of related peptides. The reported figure depends on the detection wavelength, usually 214 nanometers for peptides.
Sealed vials kept cold and dry retain potency for years in many cases. Exposure to warmth or moisture accelerates degradation. A stated expiration date is a supplier estimate rather than a measured endpoint.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.